The fact that low density lipoprotein (LDL) from multiple animal species binds to the human LDL receptor suggested that the LDL-receptor binding domain of apoprotein (apo) B must be evolutionarily conserved. To determine if a common receptor domain epitope existed on apo B, we generated a monoclonal antibody that was specific for the LDL-receptor domain of apo B. This was accomplished by using a screening procedure that selected for a hybridoma supernatant that could block specific cellular uptake and degradation of LDL. Western blots showed that this antibody, termed MB47, was specific for apo B-100. Fluid phase assays indicated a high binding affinity (Ka = 4 x 10 9 M" 1 ) and demonstrated that all human LDL particles expressed the MB47 epitope. Scatchard analysis indicated that a maximum of one MB47 molecule bound to each LDL particle. In solid phase assays, antibody MB47 bound to plasma or LDL of multiple mammalian species, including guinea pig, rabbit, pig, dog, cat, seal, whale, bear, and lion, but it did not bind to mouse or rat LDL. In contrast, a rabbit antiserum to LDL and two other anti-apo B monoclonal antibodies, MB3 and MB19, which do not bind to the receptor domain, were specific only for human LDL. LDL from multiple species, including mouse LDL, competed effectively with 125 l-human LDL for binding to human fibroblasts. MB47 effectively inhibited uptake and degradation of labeled human, guinea pig, and rabbit LDL by both human and guinea pig fibroblasts. We conclude that antibody MB47 binds to a single receptor domain on LDL and identifies a vital region conserved through mammalian evolution. (Arteriosclerosis 6:178-188, March/April 1986) A poprotein (apo) B-100 is the major apoprotein in human and other mammalian low density lipoprotein (LDL), and it mediates binding of LDL to the cellular LDL receptor.
l-human LDL for binding to human fibroblasts. MB47 effectively inhibited uptake and degradation of labeled human, guinea pig, and rabbit LDL by both human and guinea pig fibroblasts. We conclude that antibody MB47 binds to a single receptor domain on LDL and identifies a vital region conserved through mammalian evolution. (Arteriosclerosis 6:178-188, March/April 1986) A poprotein (apo) B-100 is the major apoprotein in human and other mammalian low density lipoprotein (LDL), and it mediates binding of LDL to the cellular LDL receptor. 1 Previous studies have delineated the central role of the LDL receptor in mammalian lipoprotein metabolism. 2 The fact that LDL isolated from multiple animal species binds specifically to the human LDL receptor 34 strongly suggests that at least certain portions of the receptor domain(s) of the apo B molecule must be conserved. Rabbit antisera specific for human LDL recognize heterologous LDLs poorly, 56 but this may simply mean that they contain only low titers of antibodies against the receptor domain epitope(s). Recently, several investigators have developed monoclonal antibodies against apo B and these have been useful in exploring apo B antigenic structure and metabolism. 7 " 9 We hypothesized that a monoclonal antibody directed against an epitope in the LDL-receptor binding domain(s) of human apo B also would bind heterologous apo B, while antibodies directed against epitopes not involved in receptor binding (and hence not conserved) would show little reactivity against heterologous LDLs. To test this hypothesis, we screened for and cloned a specific, anti-apo B monoclonal antibody, designated MB47, which bound LDL with high affinity and totally blocked binding of human LDL to the LDL receptor on human fibroblasts. We showed that antibody MB47 recognized an epitope in plasma and LDL from most mammalian species. In contrast, several other specific anti-apo B monoclonal antibodies, which did not block uptake of LDL by the LDL receptor, did not bind heterologous LDLs. We further showed that antibody MB47 blocked cellular uptake not only of human LDL but also of heterologous LDLs, both by human and heterologous fibroblasts. These findings provide immunochemical evidence that the receptor domain of apo B is a vital region that is highly conserved through mammalian evolution.
Methods

Preparation of Human and Heterologous Llpoprotelns
Fresh plasmas were obtained from humans and various animal species. Asian lion and spectacled bear plasmas were a generous gift of Kurt Benirschke, University of California, San Diego. Shark, seal, whale, and tuna plasmas were obtained from Jeff Graham and Randy Davis at Scripps Institute of Oceanography, La Jolla, California. In addition, hemolymph was isolated from a lobster.
Human and animal lipoprotein fractions were isolated at the following densities: very low density lipoprotein (VLDL) d < 1.006 g/ml; LDL, d = 1.025-1.050 g/ml; high density lipoprotein (HDL) d = 1.070-1.21 g/ml, and LDS (d > 1.21 g/ml). In some cases, human LDL was also isolated at d = 1.019-1.063 g/ml or at 1.045-1.065 g/ml. The protein concentration of plasma and each fraction was determined by the Lowry technique with use of a BSA standard. 10 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) of the animal LDL fractions indicated that over 85% of the protein was apo B. For each LDL and VLDL fraction, estimations of apo B content were also made following precipitation of apo B with tetramethylurea 11 or isopropyl alcohol. 12 Human apo E and apo E-DMPC liposomes were kindly supplied by Thomas Innerarity of the Gladstone Laboratories.
Modification of Low Density Lipoprotein
Methylated, 13 reductively glucosylated, 14 acetylated, 15 carbamylated, 16 and cyclohexanedione 17 modified LDL were prepared as described. Extensive derivation of each preparation was confirmed by a trinitrobenzene-sulfonic acid assay. 18 The ability of native and modified LDLs to compete with native LDL for binding to MB47 was assessed in a competitive solid phase radioimmunoassay (RIA).
Monoclonal Antibody Screening and Production
Balb/C mice were immunized with a narrow density fraction of human LDL (d = 1.045-1.065 g/ml) isolated from a single donor. 8 SDS-PAGE of the immunizing LDL revealed only apo B-100. This narrow density fraction was used because we were simultaneously attempting to develop monoclonal antibodies that selectively recognized different density fractions of LDL (data not reported here). A single fusion was performed with the P3xAg 8.653.1 myeloma according to previously described techniques. 8 Primary screening of hybridoma supernatants colonies was performed after 14 days of growth with a solid phase RIA by using microtiter plates coated with human LDL. 8 We then assessed the ability of those supematants containing anti-LDL antibodies to inhibit degradation of 125 I-LDL by human fibroblasts. LDL was iodinated with 12S I (specific activity, 200 cpm/ng) by using the iodine monochloride technique. 19 To allow antibody-LDL interaction, 0.1 ml of each hybridoma supernatant was preincubated with 1 2 5 I-LDL (final concentration, 2.5 Aig/ml) in 0.4 ml of Dulbecco's modified Eagle medium (DMEM) containing 2.5 mg/ml lipoprotein-deficient serum (LDS) for 12 hours at 4° C. Then, the individually preincubated mixtures were transferred to human foreskin fibroblast monolayers grown in DMEM with 10% fetal calf serum (FCS) in 10 mm wells. LDL receptors of these cells had been maximally expressed by prior incubation for 24 hours in DMEM containing 2.5 mg/ml LDS. 20 After incubation for 6 hours at 37° C, the cellular degradation of 12S I-LDL was assessed. 3 Control cultures had 0.4 ml of DMEM containing 125 I-LDL and one of the following: 1)0.1 ml of fresh hybridoma medium containing 20% FCS; 2) 0.1 ml hybridoma medium from wells of hybridoma colonies that were negative for apo B specific antibody production; 3) 0.1 ml DMEM containing 2.5 mg/ml LDS; or 4) 0.1 ml unlabeled LDL (to bring final unlabeled LDL concentration in the media to 500 ^ig/ml).
This screening procedure identified only one hybridoma supernatant that produced marked inhibition of LDL degradation by fibroblasts (see results below). After cloning as previously described, 8 the hybridoma cells (designated 30C2) were injected intraperitoneally into Balb/C mice for production of ascites fluid. The immunoglobin heavy chain of the antibody, designated MB47, was identified by double immunodiffusion as an lgG2a. Specificity of antibody MB47 for apo B was demonstrated by Western blots of lipoproteins separated by 2% to 16% SDS-PAGE exactly as described. 8 
Purification of Antl-LDL Immunoglobulln
Purified antibody MB47 was prepared by chromatography of the ascites fluid on a human LDL-Sepharose 4B column 89 or on a protein A-Sepharose 4B column (Pharmacia Fine Chemicals). The antibody was eluted from the LDL column with 0.1 M citric acid or 3 M potassium iodide, and was eluted from the protein A column by 0.1 M acetic acid. The antibody purified from the LDL column was used for production of Fab fragments, cell culture studies, and for fluid phase binding studies.
Preparation of Fab Fragments
Fab fragments of immunopurified antibody MB47 were formed by digestion with papain 21 and the Fc portion and undigested antibody removed by passage over a protein A-Sepharose 4B column. 22 SDS-PAGE of the Fab fragments revealed two discrete bands of 25,000 and 40,000 daltons. Immunoreactivity of the Fab fragments was verified by specific binding to LDL in a solid phase RIA.
22
Fluid Phase Radlolmmunoassays
To determine the fraction of 125 I-LDL particles bound by antibody MB47, a fluid phase RIA was utilized. 8 ' a -2 * Two different LDL (d = 1.019-1.063 g/ml) preparations were tested, one isolated from the pooled plasma of 10 normal subjects and one isolated from the plasma of one normal subject.
12S
I-LDL (2000 cpm/ng) prepared with the lodogen (Pierce Chemical Company) technique 25 was >90% trichloroacetic acid (TCA) precipitable. It was diluted in 9% bovine serum albumin (BSA) and spun at 30,000 g for 15 minutes before each assay to remove the aggregated material. The assays were performed in 12 x 75 mm glass tubes in triplicate in 55 mM barbital buffer, pH 8, containing 150 mM NaCI, 0.02% Na Azide, 3% BSA, and 1.5 mM Na-EDTA. To 0.1 ml of 12S I-LDL (containing 20 ng LDL protein) was added 0.1 ml of buffer or competing antigen and 0.1 ml of increasing concentrations of immunopurified antibody MB47 diluted in the BSA-barbital buffer. After 18 hours at 4° C, 0.1 ml of IgSORB (The Enzyme Company, Boston, Massachusetts) was added. After 2 hours, 2 ml of BSAfree barbital buffer was added, and the tubes were immediately spun at 1500 g for 60 minutes. The precipitates were washed twice with barbital buffer. The maximum precipitable radioactivity was determined by replacing the IgSORB with 100% TCA. The minimum precipitable radioactivity was determined in the absence of antibody MB47. The percent 125-LDL bound was then calculated as previously described. 8 
Determination of Stolchlometry of MB47 Binding
Immunopurified antibody MB47 was iodinated with 125 I by the lodogen technique (specific activity, 3000 cpm/ng). Following extensive dialysis against PBS, over 95% of the radioactivity was precipitable by 10% TCA. More than 98% of the 125 I-MB47 bound to an LDL column. Assays were performed in triplicate in 10 x 75 mm silicon-coated glass tubes. Increasing concentrations of 12S I-MB47 in 0.1 ml of BSA-barbital buffer were added to 100 ng of pooled, normal human LDL diluted in 0.2 ml of BSA-barbital buffer. Each tube contained 182 fmol of LDL apo B (based on an apo B MW of 550,000). After incubation for 16 hours at 4°C
, the LDL was quantitatively precipitated by a rabbit antiserum specific for human LDL. (Only the d > 1.21 g/ml fraction of the rabbit antiserum was used, as antibody MB47 binds rabbit apo B). Preliminary experiments established a concentration of delipidated rabbit antiserum that precipitated more than 98% of 100 ng of 12S l-human LDL. After the addition of the rabbit antibody, the tubes were incubated for 16 hours at 4° C, and then spun at 1500 gfor 60 minutes at 4° C. The supernatants were removed, and the pellets were washed twice with 2 ml of ice-cold barbital buffer. Nonspecific binding and precipitation were determined in two sets of parallel tubes. In the first set, no human LDL was added to the initial incubation, but the same amount of rabbit second antibody was added. In the second set of tubes, nonimmune rabbit serum (d > 1.21 g/ml fraction) was substituted for the immune rabbit serum. Both methods yielded identical values for nonspecific binding, which was linear with increasing concentrations of 1 2 5 I-MB47 antibody, and in all cases was less than 1 % of the total counts added. Specific 12S I-MB47 binding to LDL was obtained by subtracting nonspecific binding from total binding. Binding data was analyzed by a linear regression program for Scatchard analysis of ligand binding systems, which provided an estimate of the antibody affinity constant (Ka) and the receptor or epitope concentration.
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LDL Binding to an MB47-Sepharose 4B Column
Antibody MB47 (50 mg, purified on a protein A column) was bound to 12 ml of activated Sepharose 4B, according to the instructions of the manufacturer (Pharmacia Fine Chemicals). Subsequent studies showed that the MB47-Sepharose 4B immunoadsorbant column bound 3 mg of LDL/ml of gel.
Solid Phase Radlolmmunoassays
Competitive solid phase RIAs for human apo B were performed with antibody MB47, the rabbit antiserum to human LDL, and two previously characterized mouse monoclonal antibodies against human apo B, B3 and B19. 827 In this report, B3 and B19 are termed MB3 and MB19, respectively. Polyvinyl chloride wells were coated with 0.05 ml of human LDL diluted to 10 ^g/ml in PBS (pH 7.35), and incubated for 2 hours at 37° C; the remaining binding sites were blocked by coating with 5% BSA in PBS for 30 minutes at room temperature. The plates were then washed with PBS washing buffer containing 0.1% BSA, 0.01% azide, and 0.05% Tween-20. Fresh human LDL, prepared from pooled normal plasma, was used for the standard curve in dilutions ranging from 0.4 /xg/ml to 97.2 nQ/m\. All dilutions were made in a PBS buffer containing 3% BSA, 0.01 % Na azide, and 0.05% Tween-20. The standard LDL or competitors (0.025 ml) were added to the LDLcoated wells followed by 0.025 ml of buffer containing a fixed, limiting amount of monoclonal antibody (ascites fluid) or rabbit antiserum. The optimal final concentration of antibody was determined from preliminary antibody dilution experiments and was chosen as the amount of antibody resulting in 50% of maximum binding. The plates were incubated for 18 hours at 4° C, then washed with the PBS washing buffer. Mouse or rabbit antibody binding was then quantitated by adding 0.05 ml of 12S l-immunopurified goat antimouse Ig or 125 I goat antirabbit Ig (40 ng/well, 8000 cpm/ng). After 4 hours of incubation at 4° C, the plates were washed and the individual wells were counted. The results were plotted as B/Bo vs log standard concentration, where B and Bo are specific counts bound in the presence and absence of competitor, respectively.
To check for the ability of rat or mouse plasma to bind antibody MB47, a solid phase assay was used in which antibody MB47 was bound to the plastic wells. Wells were coated with 0.05 ml of immunopurified antibody MB47 (10 /ig/ml in PBS); the remaining binding sites were coated with 5% BSA in PBS. Competitor and human 12S I-LDL (10 ng, 5000 cpm/ng) were added simultaneously to the MB47-coated wells. After 16 hours of incubation, the plates were washed, and the wells were counted.
Studies with Cultured Flbroblasts
Using established techniques, we tested the ability of antibody MB47 and MB47 Fab fragments to block specific LDL binding, 28 ' M intemalization, 20 and degradation. 3 Studies were also performed to test the ability of antibody MB47 to inhibit binding and degradation of iodinated rabbit, guinea pig, and human LDL to both guinea pig fibroblasts and human fibroblasts. 30 Using the same techniques, we performed studies to test the ability of human LDL and heterologous LDL samples to compete with human 125 I-LDL for uptake by human fibroblasts.
Results
Antibody Screening and Antibody Specificity
Previously, Curtiss and Edgington 8 reported the production and characterization of 11 apo B-specific monoclonal antibodies. None of these antibodies inhibited 12S I-LDL uptake and degradation by cultured fibroblasts (S. G. Young and T. Innerarity, personal communications). In this study, we report a screening technique for identifying apo B specific hybridomas that secrete antibodies with the ability to block 12S I-LDL uptake by fibroblasts. From a single fusion, we identified 48 hybridoma colonies that produced antibodies that bound LDL. When directly tested for their ability to inhibit LDL uptake, several supernatants produced minor degrees of inhibition of LDL uptake (Figure 1 ). However, only one supernatant, No. 47, produced marked inhibition of LDL uptake and degradation. Following cloning, the specificity of antibody MB47 was demonstrated by Westem blot analysis. 8 antibody MB47 bound apo B-100 of human LDL and VLDL but not to apo B-48 of chylomicrons. Western blots also showed that Antibody MB47 reacted with the high molecular weight (MW) apo B of dog, pig, guinea pig, and rabbit, but not with apo B of the mouse. 
Characterization of MB47 Binding to LDL
Previous studies suggested that apo B epitopes recognized by some monoclonals are not expressed by all LDL particles. 8 ' 23 An excess of certain monoclonal antibodies does not result in complete binding of all To assess the average affinity constant of antibody MB47 for LDL, competitive equilibrium fluid phase RIAs were performed. Homologous unlabeled LDL produced full displacement of 12S I-LDL, and the calculated affinity constant of antibody MB47 for LDL was 4.06 x 10 s M" 1 , somewhat higher than the values reported by Tsao et al. 27 for 11 other apo B-specific monoclonal antibodies.
We also used a MB47-Sepharose 4B immunoadsorbant column as another means to assess the percentage of LDL particles that expressed the MB47 epitope. The column had a total LDL binding capacity of greater than 36 mg of LDL protein. When 10 mg of LDL protein was added to the column and incubated overnight at 4° C, over 99% of the added LDL protein was bound.
Stolchlometry of MB47 Binding to LDL
To determine the number of antibody binding sites per apo B molecule, a different fluid phase assay was used in which an increasing amount of immunopurified 125 I-MB47 antibody was added to a fixed concentration of LDL. The amount of 
MB47 Binding to Modified LDLs and Apo E
Using solid phase competitive RIAs, we assessed the ability of chemically modified LDLs to bind to antibody MB47. Compared to equivalent amounts of native LDL, methylated LDL showed essentially no immunoreactivity to antibody MB47. Acetyl LDL, glucosylated LDL, and carbonyl LDL showed a reduced ability to bind to antibody MB47. Cyclohexanedione modification of LDL did not alter immunoreactivity to antibody MB47.
Because apo E also binds to the LDL receptor, we tested whether MB47 might bind to apo E. However, when tested in a competitive RIA, neither apo E nor apo E-DMPC liposomes (even when added at 0.2 mg/ml) competed with LDL for binding to antibody MB47. A similar result was seen when using the rabbit antiserum as antibody source. 
MB47 Binding to Heterologous Plasma and Llpoproteln Fractions
Using a solid phase RIA, we tested the ability of heterologous whole plasma to compete with human LDL for antibody MB47 binding (Figure 4 ). All mammalian plasmas tested, except for mouse and rat, effectively competed for MB47 binding. Whale plasma was also a good competitor (data not shown). The spectacled bear plasma was the best competitor, due to its high lipoprotein levels (total cholesterol 402 mg/dl, triglycerides 1013 mg/dl) and strong reactivity of antibody MB47 for bear apo B ( Figure 5 ). Lobster hemolymph, shark plasma, and plasma from three species of tuna showed no reactivity with MB47. However, undiluted plasma from one species of tuna consistently showed approximately 30% inhibition of MB47 binding to coated human LDL. None of the heterologous lipoproteindeficient plasmas showed competition. When similar RIAs were performed by using either of two previously described apo B-specific monoclonal antibodies, MB3 and MB19, or a polyclonal rabbit antiserum specific for human LDL, no competition was seen with the heterologous plasmas ( Figure 6 ). Thus, the human apo B epitopes recognized by antibodies MB3 and MB19, and the rabbit antibodies are unique to human apo B.
The ability of isolated lipoproteins from multiple species to compete with human LDL for antibody MB47 binding was also tested. The LDL of each species tested, except for the mouse, was an effective competitor ( Figure 5 ). Microtiter wells were coated with pooled human LDL, and MB47 asdtes fluid was used at 1:20,000 dilution. The amount of antibody MB47 bound to the solid phase LDL was quantitated with a subsequent incubation with 12S l-goat antimouse IgG. Each lipoprotein-deficient plasma was diluted to the same protein concentration as the plasma from which it was isolated. For reference, the competition curve of human plasma is also shown in B. Whale LDL also was an effective competitor, but rat LDL was not (data not shown). Although LDL of most species did not compete as well as human LDL, bear LDL was a better competitor. As expected, heterologous LDL fractions did not compete in similar assays when using MB3, MB19, or the polyclonal rabbit antiserum. Human VLDL as well as heterologous VLDL samples were effective competitors for binding to antibody MB47. the rabbit, pig, guinea pig, bear, seal, and whale, antibody MB47 bound LDL and VLDL of each of these species, whereas antibodies MB3 and MB19 did not.
MB47 Inhibition of Cellular LDL Uptake and Degradation
antibody MB47 was selected in the initial screening studies because it inhibited fibroblast uptake of 125 I-LDL. Further studies performed after the hybridoma-producing antibody MB47 was cloned demonstrated that this effect was due to marked inhibition of specific 125 I-LDL binding (Figure 8 ). Inhibition of specific binding, internalization, and degradation by antibody MB47 was comparable to that produced by a 200-fold excess of unlabeled LDL.
It is possible that antibody MB47 binds to an epitope adjacent to the apo B receptor domain, and because of its size, sterically hinders the binding of apo B to the LDL receptor. Therefore, the capacity of Fab fragments of antibody MB47 to inhibit human LDL uptake and degradation were also tested. MB47-Fab fragments completely blocked specific cellular binding and degradation of LDL ( Figure 9) .
Next, the concentration of antibody MB47 required for maximal inhibition of LDL degradation was assessed. Since antibody MB47 bound heterologous LDL, we also tested whether MB47 would block the uptake and degradation of heterologous LDL by heterologous fibroblasts. This was accomplished by testing the ability of immunopurifled antibody MB47 to inhibit cellular uptake and degradation of iodinated human, rabbit, and guinea pig LDL preparations on human as well as guinea pig fibroblasts. At a molar ratio of IgG to LDL of 1, there was nearly complete inhibition of 125 l-human LDL degradation by human fibroblasts (Figure 10 A) . The molar ratio required for maximal inhibition of rabbit LDL or guinea pig LDL uptake and degradation was 4:1 to 8:1, consistent with the solid phase RIA data, which showed that antibody MB47 bound human LDL better than guinea pig and rabbit LDL. The maximal degree of inhibition caused by high MB47 concentrations was less for the guinea pig and rabbit LDL preparations than for the human LDL. Antibody MB47 inhibited human LDL degradation by human fibroblasts by 95%, but the maximal inhibition of rabbit and guinea pig LDL degradation was 55% and 75%, respectively. (A 200-fold excess of unlabeled human LDL inhibited uptake and degradation of all three tracers by over 95%). In part, the inability of antibody MB47 to completely inhibit specific degradation of guinea pig and rabbit LDL preparations may have been due to the presence of apo E-containing lipoproteins in the LDL density range in these animals. When subjected to SDS-PAGE, a small band consistent with apo E was seen in both guinea pig and rabbit LDL preparations. Parallel studies on guinea pig fibroblasts with use of the same iodinated LDL preparations showed similar results (Figure 10 B) . Again, a 1:1 molar ratio of antibody MB47/LDL-apo B resulted in nearly complete inhibition of human LDL degradation, whereas higher antibody con- Inhibition by antibody MB47 and excess unlabeled human LDL of 125 l-human LDL binding, internalization, and degradation by cultured human fibroblasts. Fibroblast monolayers were grown in 35 mm wells in Dulbecco's modified Eagle medium (DMEM) containing 10% fetal calf serum. Rbroblast LDL-receptors were stimulated by a 24-hour preincubation with DMEM containing 2.5 mg/ml of lipoprotein-deficient serum (LDS). DMEM-LDS containing 2.5 ^g/ml of 12S I-LDL and either 20% of MB47 hybridoma culture supernatant (vol/vol) or a 200-fold excess of unlabeled LDL (final concentration, 500 /xg/ml) were preincubated for 16 hours at 4° C before being placed on the fibroblast monolayers. Determinations of binding, internalization, and degradation were performed in triplicate, and expressed as a percentage of control values determined in the absence of antibody MB47. The baseline values (100%) for binding, Internalization, and degradation of 2.5 /tg/ml 12S I-LDL were 23 ng/mg cell protein, 0.1 cell protein, and 0.5 jtg/mg cell protein, respectivety. centrations were required for maximal inhibition of guinea pig and rabbit LDL degradation.
Because antibody MB47 bound all LDLs except for mouse and rat, we tested whether human and mouse LDLapo B shared a common region recognized by the human LDL receptor. We assessed the ability of human LDL and mouse LDL (and other heterologous LDL preparations) to Inhibit 12S l-human LDL binding and uptake by human fibroblasts. The concentration of 125 l-human LDL in the fibroblast media was kept constant, and increasing amounts of human or heterologous LDL were added (Figure 11 ). Human and pig LDL were the best competitors. Mouse LDL competed as well as rabbit, guinea pig, or dog LDL, although not as well as human LDL. Interestingly, the ability of guinea pig, rabbit, and dog LDL-apo B to compete with 125 l-human LDL for cellular binding roughly correlated with their ability to compete with human LDL for MB47 binding in the radioimmunoassays (Figure 6 ). Pig LDL was a better competitor in the fibroblast system than in the FtlA.
Discussion
We have demonstrated that LDL isolated from multiple animal species will bind specifically to the human LDLreceptor ( Figure 11 ) and, in turn, that human LDL will bind to specific LDL-receptors present on heterologous fibroblasts (Figure 10 B) . These observations are in agreement with the results of others 34 and suggest that apo B must contain a highly conserved domain that mediates binding to the cellular LDL-receptor. However, we ( Figure 5 A) and others 5 ' 6 have noted that rabbit antisera generated against human LDL have little reactivity toward heterologous LDL in RIAs, suggesting that few antibodies in the antisera are directed toward common, conserved epitopes. Presumably this occurs because the rabbit, when immunized with human LDL, makes few antibodies against the receptor domain of apo B, which is conserved, but makes many antibodies to nonnomologous domains, which are present in portions of apo B not involved in receptor binding. Indeed, when using MB3 and MB19 ( Figure 5) we found that . Individual media containing increasing amounts of antibody MB47 and a constant amount of 12S I-LDL were preincubated for 16 hours at 4° C before being placed on fibroblast monolayers for incubation at 37° C for 6 hours. The concentration of MB47 in the media is expressed as the molar ratio of MB47/tetramethylurea-insoluble 125 I-LDL added (based on a MW of apo 550,000 and MW of MB47 of 166,000). Degradation of each LDL is expressed as the percentage of a control value in the absence of MB47. Each point is the mean of triplicate determinations. On human fibroblasts, the baseline (100%) values for degradation of 2.5 /ig/ml of 12S I-LDL were 0.75 /ig/mg cell protein for the human LDL, 0.1 ^Q/mg cell protein for the guinea pig LDL, and 0.15 uglmg cell protein for the rabbit LDL. Similar values were obtained with guinea pig fibroblasts. Binding studies were also performed and showed identical patterns of inhibition. On both types of fibroblasts and for all three iodinated LDL preparations, excess unlabeled human LDL (500 jtg/ml) inhibited over 95% of LDL binding and degradation.
antibodies that did not bind to the LDL-receptor binding domain (i.e., they did not block 125 I-LDL binding to fibroblasts) did not bind to LDL of other species. Similar results were obtained with two other previously characterized antibodies 8 against apo B (B11 and B20), which do not bind to the LDL-receptor binding domain (data not shown). This evidence suggests that domains not involved in receptor binding are less likely to be conserved, but it is certainly possible that some such domain may be conserved.
For reasons noted above, we postulated that a monoclonal antibody specifically selected because it was directed against the LDL-receptor binding domain of apo B would be likely to bind to LDL of many species. Therefore, we developed an appropriate screening procedure and succeeded in isolating one such LDL-receptor domain monoclonal antibody, MB47. We showed that this antibody binds to a highly conserved apo B epitope.
Antibody MB47 specifically bound apo B-100 in human LDL and VLDL, but did not bind to apo B-48. Its apparent affinity constant (Ka) for human LDL, assessed by competitive RIA, was 4 x 10 9 M-1 .Scatchard analysis indicated that there was only one high affinity epitope expressed per LDL particle, consistent with previous reports.
24 ' 31 This suggests that there is only one LDL-receptor binding domain per LDL particle (if we assume that the MW of apo B is 550,000). Furthermore, all binding sites appeared to be of similar configuration (i.e., the slope of the Scatchard plot was linear).
Several investigators have demonstrated substantial immunochemical heterogeneity in LDL.
822 ' 23 That is, some apo B epitopes are not expressed by all LDL particles. If the LDL-receptor binding domain of apo B were not expressed on every LDL particle, it would suggest the possibility that LDL might be metabolically heterogeneous. However, using either fluid phase RIAs or immunoaffinity chromatography, we found that all 125 I-LDL particles in solution expressed the MB47 epitope. This latter property suggests that MB47 should be a useful monoclonal antibody for a RIA designed to quantitate apo B in plasma. Indeed, preliminary studies with over 100 plasma samples indicated that MB47 accurately measures total plasma apo B in all of them.
Two previously described monoclonal antibodies that did not block cellular uptake of LDL, MB3 and MB19, bound only to human LDL and not to heterologous LDLs.
Thus, it appears that epitopes not critically involved in binding to the cellular LDL-receptor may not be conserved. Similarly, Mao et al. 32 found that their mouse monoclonal antibodies against human apo B did not bind pig LDL. 32 Whether these monoclonals bound to the apo B receptor domain was not reported. Interestingly, they did find that a mouse antiserum against human LDL recognized some shared epitopes in pig and human LDL. Our rabbit antiserum against human LDL showed little, if any, ability to bind epitopes present in heterologous plasmas (Figure 3  A) . However, in separate experiments (data not shown), we have found that the polyclonal rabbit antiserum does compete with 125 I-MB47 antibody for LDL binding in a solid phase RIA, but only under conditions of marked rabbit antibody excess. This suggests that the polyclonal antiserum does contain a few antibodies against the conserved receptor domain of apo B. Obviously, the predominant populations of antibodies in the rabbit antiserum were directed against the regions of apo B not conserved and not directly involved in LDL-receptor binding. Similarly, we found that only one of the 48 mouse hybridoma supernatants producing anti-LDL antibodies had a significant ability to markedly inhibit LDL uptake by cultured fibroblasts. Previously, Curtiss and Edgington 8 developed 13 monoclonal antibodies specific for apo B, and none bound to a receptor domain epitope. In contrast, two of seven monoclonals developed by Tikkanen et al. 9 and five of seven analyzed by Milne et al. 22 were capable of blocking LDL uptake by cultured fibroblasts.
Antibody MB47 completely inhibited receptor-mediated binding, intemalization, and degradation of human LDL by human fibroblasts (Figure 8 ). This inhibition was complete when the antibody MB47/LDL-apo B molar ratio in the fibroblast media was 1:1 ( Figure 10 ). Fab fragments of MB47 were also effective in totally blocking receptor-mediated LDL uptake (Figure 9 ), although the molar ratio of Fab fragments to LDL-apo B in the fibroblast media required for complete inhibition of LDL uptake was 4:1 to 8:1, higher than that for intact antibody MB47 (Figure 10 ). This is most likely due to a lower affinity of Fab fragments for LDL compared to that of intact immunoglobulin. 24 Milne et al. 22 have previously reported that Fab fragments of certain anti-apo B monoclonal antibodies may block binding of LDL. Antibody MB47 bound to the plasma, or isolated LDL or VLDL, of each mammalian species tested, except for the 20 
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100 TMU Insoluble LDL Protein Added (^g/ml) 1 eo mouse and a closely related species, the rat ( Figures  4,6,7) . No immunoreactivitiy was observed in the plasma of more primitive species, such as shark, lobster, or tuna fish. Western blots confirmed that antibody MB47 bound to apo B-100 (or an analogous high MW protein) of dog, pig, guinea pig, and rabbit, but not mouse. Antibody MB47 was also capable of inhibiting the cellular uptake of heterolo gous LDLs by either human or guinea pig fibroblasts.
The fact that monoclonal antibody MB47, as well as Fab fragments of MB47, bind to a conserved region of apo B and the fact that it also blocks the cellular uptake of both human and heterologous LDL samples strongly support the suggestion that antibody MB47 binds to the receptor domain of apo B-100. However, our present data cannot exclude the possibility that antibody MB47 binds to a conserved epitope adjacent to, or even distant from, the receptor domain and blocks LDL binding to cells by steric hindrance or by inducing a conformational change in apo B. If MB47 binds to the LDL-receptor binding domain of apo B-100, how does one explain the observation that both mouse and rat apo B bind to the human LDL receptor, although neither reacts with antibody MB47? It is likely that subtle structural differences exist between the receptor domain of mouse and human apo B, which are insufficient to interfere with recognition by the receptor but can be distinguished immunochemically. In fact, this would explain why we and others have been able to develop mouse monoclonal antibodies against the receptor domain of human apo B.
7 ' 9 The ability of monoclonal antibodies to detect such subtle differences in antigenic structure is well known.
Because a conserved region of apo B exists and because heterologous LDLs bind to the cellular LDL-receptor of multiple species, it follows that a significant conservation of the LDL-binding domain of the LDL-receptor must also exist. Biesiegel et al. 3334 and Huettinger et al. 35 have provided immunochemical evidence for conservation of portions of the cellular LDL receptor using a rabbit antiserum to the bovine LDL receptor and specific mouse monoclonal antibodies. One mouse monoclonal antibody, lgG-C7 detected an epitope shared by human and bovine LDL receptors, and it effectively competed with human LDL for cellular LDL-receptor binding. However, this mouse monoclonal antibody did not bind to the LDL-receptor of mouse cells, even though these cells contained a receptor that bound human LDL-apo B. (In an analogous fashion, antibody MB47 did not bind mouse LDL, although mouse LDL bound to the human LDL receptor.)
Further evidence that proteins with important roles in lipoprotein metabolism contain conserved sequences of importance in biologic function are found in recent studies by Weisgraber and colleagues. 36 They demonstrated conservation of the binding domain of apo E, another ligand that binds to the LDL-receptor. Using mouse monoclonal antibodies developed by Milne et al., 3 'they showed that an antibody against the binding receptor domain of human apo E also bound to canine apo E.
While this manuscript was in preparation, Schonfeld and colleagues 38 ' M reported similar findings. They studied the abiity of seven previously characterized anti-apo B monoclonal antibodies to bind to LDL isolated from a number of animal species. Two of the seven antibodies, which had previously been shown to block 125 I LDL uptake on fibroblasts, bound LDL of other animal species. Each antibody bound to one epitope on LDL. The five monoclonals that did not block 12S I-LDL uptake and degradation showed little reactivity with heterologous LDL.
